Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
National University Hospital
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Stephanie Saw
Dr Ross Soo
Published by HT Digital Content Services with permission from Health Daily ...